trending Market Intelligence /marketintelligence/en/news-insights/trending/jpx81pjawbxje30n1szwvw2 content esgSubNav
In This List

Diffusion executes 1-for-15 reverse stock split to maintain Nasdaq listing

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Diffusion executes 1-for-15 reverse stock split to maintain Nasdaq listing

Diffusion Pharmaceuticals Inc. executed a 1-for-15 reverse stock split of its common shares to maintain its listing on the Nasdaq capital market.

The company's shareholders and board of directors approved the reverse stock split on June 14 and Nov. 30, respectively. The action reduced the number of the company's outstanding common shares to about 3.4 million from about 50.6 million before the reverse split.

Charlottesville, Va.-based Diffusion develops therapies for cancer. Its lead product transcrocetinate sodium has initiated phase 3 trials for treating glioblastoma multiforme, a type of brain cancer; phase 2 studies for treating pancreatic cancer; phase 2/3 trials for treating metastatic brain cancer and a phase 2 trial for treating stroke.